A comprehensive view of Oral Medicines / Supplements. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Government & Public Policy Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

FDA approves Roche's oral Alecensa for ALK-positive early-stage lung cancer treatment following successful Phase 3 trial; trial results show Alecensa reduced the risk of disease recurrence or death by 76%
Published: April 19, 2024 by F. Hoffmann-La Roche Ltd. (Roche)
AbbVie announces late-breaking data at AAN supporting long-term safety and efficacy of oral Atogepant QULIPTA for preventive treatment of migraine; 70% of subjects achieved over 50% reduction in monthly migraine days
Published: April 12, 2024 by AbbVie Inc.
The FDA approves ViiV Healthcare’s Dovato (dolutegravir/lamivudine) for adolescents aged 12 and above for the treatment of HIV-1 infection; Dovato offers a single-tablet, two-drug oral regimen for HIV therapy
Published: April 08, 2024 by GSK Group (GlaxoSmithKline)
Boehringer Ingelheim and Eli Lilly report results from EMPACT-MI Phase 3 trial of Jardiance (empagliflozin)
Published: April 06, 2024 by Eli Lilly & Co.
Bristol Myers BMY's late-stage study on Zeposia, an oral drug for Crohn's disease, fails to achieve its primary endpoint in clinical trials; the company did not disclose specific details or future plans for the drug
Published: April 01, 2024 by Zack's Commentary

Ask us about our Government & Public Policy market view

Trending Chart

Interactive chart with headline count